HealthDay on MSN7h
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast CancerFor patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...
David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.
BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...
Industry giants like Takeda Pharmaceuticals, Pfizer, Novartis, and Bayer are revolutionizing treatment landscapes, paving the way for enhanced patien ...
Metronomic chemotherapy (MC) is emerging as a groundbreaking treatment for pediatric neuroblastoma, offering a more accessible and manageable option for children with high-risk and relapsed/refractory ...
Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...
Metronomic chemotherapy (MC) is emerging as a groundbreaking treatment for pediatric neuroblastoma, offering a more accessible and manageable option ...
Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...
The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...
A survey of 500 construction workers shared exclusively with the Daily Mail has uncovered a terrifying lack of understanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback